Phase I Clinical and Pharmacokinetic Study of LU103793 (Cemadotin Hydrochloride) as an Intravenous Bolus Injection in Patients with Metastatic Solid Tumors

1996 ◽  
Vol 19 (6) ◽  
pp. 490-495 ◽  
Author(s):  
K. Mross ◽  
K. Herbst ◽  
W.E. Berdel ◽  
A. Korfel ◽  
I.-M. von Broen ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Pharmacokinetic Study ◽  
Bolus Injection ◽  
Intravenous Bolus ◽  
Intravenous Bolus Injection

Phase I Clinical Trial of Lobaplatin (D-19466) after Intravenous Bolus Injection

1994 ◽  
Vol 17 (2) ◽  
pp. 142-148 ◽  
Author(s):  
H.H. Fiebig ◽  
H. Henß ◽  
K. Mross ◽  
F. Meyberg ◽  
P. Aulenbacher ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Phase I ◽  
Bolus Injection ◽  
Phase I Clinical Trial ◽  
Intravenous Bolus ◽  
Intravenous Bolus Injection

Phase I study of cancer therapy with recombinant interleukin-2 administered by intravenous bolus injection

Biotherapy ◽  
1989 ◽  
Vol 1 (3) ◽  
pp. 215-226 ◽  
Author(s):  
Evan M. Hersh ◽  
J. Lee Murray ◽  
Waun Ki Hong ◽  
Michael G. Rosenblum ◽  
James M. Reuben ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Phase I ◽  
Phase I Study ◽  
Bolus Injection ◽  
Interleukin 2 ◽  
Intravenous Bolus ◽  
Intravenous Bolus Injection ◽  
Recombinant Interleukin 2

Pharmacological properties of YM-254890, a specific Gαq/11 inhibitor, on thrombosis and neointima formation in mice

2005 ◽  
Vol 94 (07) ◽  
pp. 184-192 ◽  
Author(s):  
Masatoshi Taniguchi ◽  
Yumiko Moritani ◽  
Toshio Uemura ◽  
Takeshi Shigenaga ◽  
Hajime Takamatsu ◽  
...  
Keyword(s):  
Oral Administration ◽  
Vascular Injury ◽  
Bolus Injection ◽  
Thrombus Formation ◽  
Therapeutic Window ◽  
Pharmacological Properties ◽  
Neointima Formation ◽  
Intravenous Bolus ◽  
Test Drug ◽  
Intravenous Bolus Injection

SummaryThe pharmacological properties of YM-254890,a specific Gαq/11 inhibitor, on acute thrombosis and chronic neointima formation after vascular injury have been investigated. FeCl3 was used to induce vascular injury in the carotid artery of mice. For the thrombosis studies, the test drug was either intravenously or orally administered before vascular injury. For the neointima studies, the test drug was orally administered 1 h before and twice daily for 1 week after vascular injury. Histological analysis was then performed 3 weeks later. YM-254890 significantly inhibited ex vivo platelet aggregation 5 min after intravenous bolus injection at 0.03 mg/kg or more, and 1 h after oral administration at 1 mg/kg. YM-254890 significantly inhibited thrombus formation after intravenous bolus injection at 0.03 mg/kg as well as after oral administration at 1 mg/kg, but tail transection bleeding time was significantly prolonged at 0.1 mg/kg for intravenous injection and 3 mg/kg for oral administration. Furthermore, oral administration of YM-254890 dose-dependently inhibited neointima formation 3 weeks after vascular injury with significant effects at 1 mg/kg twice daily for 1 week. Clopidogrel also significantly inhibited neointima formation at its antithrombotic dose, but its inhibitory potency was less than that of YM-254890. However, YM-254890 significantly reduced systemic blood pressure at doses 3 times higher than those that produced significant inhibitory effects on thrombosis and neointima formation. Though the systemic use of YM-254890 may be limited, owing to its narrow therapeutic window, this unique compound is a useful research tool for investigating the physiological roles of Gαq/11.

scholarly journals Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study

2011 ◽  
Vol 17 (15) ◽  
pp. 5113-5122 ◽  
Author(s):  
Steven G. DuBois ◽  
Suzanne Shusterman ◽  
Ashish M. Ingle ◽  
Charlotte H. Ahern ◽  
Joel M. Reid ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Pharmacokinetic Study ◽  
Pediatric Patients ◽  
Oncology Group ◽  
Oncology Group Study

A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors

2009 ◽  
Vol 66 (3) ◽  
pp. 441-448 ◽  
Author(s):  
E. Gabriela Chiorean ◽  
Srikar Malireddy ◽  
Anne E. Younger ◽  
David R. Jones ◽  
Mary-Jane Waddell ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Pharmacokinetic Study ◽  
Dose Escalation ◽  
Advanced Solid Tumors

A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors

2008 ◽  
Vol 63 (5) ◽  
pp. 903-910 ◽  
Author(s):  
Claire F. Verschraegen ◽  
Keith Skubitz ◽  
Adil Daud ◽  
Andrzej P. Kudelka ◽  
Ian Rabinowitz ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Pharmacokinetic Study ◽  
Advanced Solid Tumors

scholarly journals Phase I and Pharmacokinetic Study of Sequential Paclitaxel and Trabectedin Every 2 Weeks in Patients with Advanced Solid Tumors

2010 ◽  
Vol 16 (9) ◽  
pp. 2656-2665 ◽  
Author(s):  
Quincy Chu ◽  
Alain Mita ◽  
Bahram Forouzesh ◽  
Anthony W. Tolcher ◽  
Gary Schwartz ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Pharmacokinetic Study ◽  
Advanced Solid Tumors

scholarly journals Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors

2010 ◽  
Vol 21 (2) ◽  
pp. 376-381 ◽  
Author(s):  
H.A. Wakelee ◽  
A. Patnaik ◽  
B.I. Sikic ◽  
M. Mita ◽  
N.L. Fox ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Pharmacokinetic Study ◽  
Advanced Solid Tumors

Dose-Finding Phase I Clinical and Pharmacokinetic Study of Orally Administered Irinotecan in Patients with Advanced Solid Tumors

2006 ◽  
Vol 12 (12) ◽  
pp. 3774-3781 ◽  
Author(s):  
Isa E.L.M. Kuppens ◽  
Eric Dansin ◽  
Henk Boot ◽  
Celine Feger ◽  
Sylvia Assadourian ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Pharmacokinetic Study ◽  
Dose Finding ◽  
Advanced Solid Tumors
Sign in / Sign up

Export Citation Format

Share Document